Study for Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals (Natugerin®) in Improvement of Stress and Fatigue

Azidus

Status and phase: Unknown; Phase 3

Conditions: Fatigue; Stress

Treatments: Dietary Supplement: NatusGerin; Other: Placebo capsules

Study type: Interventional

Funder types: Industry

Identifiers

NCT01228006

NATEMS0310

Version 02 - March 11, 2010

Details and patient eligibility

About

It is hoped that the group treated with Panax Ginseng, Vitamins and Minerals obtain significant reduction in levels of stress and fatigue and that the results are superior to the placebo group.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Agree with all study procedures, signing the IC in two ways, by his own free will;
• Patients older than 18 years, male or female, regardless of ethnicity or social class;
• Presence of pictures of mild to moderate stress, confirmed with the aid of the Stress Symptom Inventory (ISS), which considers stress and mild to moderate classification Alert classification Resistance;
• Presence frame of fatigue with a score greater than 36 according to the Fatigue Severity Scale (FSS).

Exclusion criteria

• Participation in clinical trials in the 12 months preceding the survey;
• Current treatment with drugs that are stimulants or central nervous system depressants such as hypnotics, anxiolytics, antipsychotics, antidepressants, statins and muscle relaxants;
• Alternative Therapies that scientifically, or have no influence in the tables of stress or fatigue as acupuncture or relaxing massages;
• Treatment psychotherapeutic medication or not;
• Current treatment or prediction of treatment with oral anticoagulants (due to interaction with the tocopherol);
• Women who are pregnant or lactating;
• Patients with lactose intolerance;
• Patients allergic to soy or peanuts;
• chronic renal failure;
• Patients using other multivitamins or individual vitamins such as vitamin D and / or A.
• Chronic alcoholism;
• Patients with clinical diagnosis of diseases causing severe chronic pain or adversely affect the clinical interpretation as fibromyalgia, multiple sclerosis, neuropathies and myopathies;
• Patients with hypothyroidism or hyperthyreosis diagnosed clinically;
• Patient history and physical examination suggestive of severe hepatorenal failure;
• Patients with decompensated diabetes mellitus (fasting glucose above 180 mg / dL);
• Patients being treated for cancer;
• Amendment of the routine of life during the study as early vacation or suspected change in working hours;
• Patients with complaints of excessive sleepiness caused by organic source frameworks such as sleep apnea and morbid obesity (BMI above 35);
• History of hypersensitivity to any component of the product under investigation;
• Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

300 participants in 2 patient groups, including a placebo group

Treatment

Experimental group

Description:

NatusGerin

Treatment:

Dietary Supplement: NatusGerin

Control

Placebo Comparator group

Description:

Gelatin capsules identical to drug test

Treatment:

Other: Placebo capsules